Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia

AIM: This study evaluates the cost–effectiveness of imipenem/cilastatin/relebactam (IMI/REL) for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in an ‘early adjustment prescribing scenario’. METHODS: An economic model was constructed to compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Naik, Jaesh, Dillon, Ryan, Massello, Matthew, Ralph, Lewis, Yang, Zhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288960/
https://www.ncbi.nlm.nih.gov/pubmed/36688591
http://dx.doi.org/10.2217/cer-2022-0113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288960/
https://www.ncbi.nlm.nih.gov/pubmed/36688591
http://dx.doi.org/10.2217/cer-2022-0113

Ejemplares similares